Goldman Sachs Maintains Neutral on BioXcel Therapeutics, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has maintained a Neutral rating on BioXcel Therapeutics (NASDAQ:BTAI) and lowered the price target from $12 to $4.
August 15, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on BioXcel Therapeutics and lowered the price target from $12 to $4.
The lowering of the price target by Goldman Sachs from $12 to $4 indicates a negative outlook for BioXcel Therapeutics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100